Switch theme
Sign up to access all valuation multiples
Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.
2000
n/a
LTM Revenue $2.6B
LTM EBITDA $123M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yixintang Pharmaceutical has a last 12-month revenue (LTM) of $2.6B and a last 12-month EBITDA of $123M.
In the most recent fiscal year, Yixintang Pharmaceutical achieved revenue of $2.5B and an EBITDA of $224M.
Yixintang Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yixintang Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Profit | $852M | XXX | $794M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $123M | XXX | $224M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $79.9M | XXX | $78.8M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $42.8M | XXX | $15.8M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Yixintang Pharmaceutical's stock price is CNY 17 (or $2).
Yixintang Pharmaceutical has current market cap of CNY 9.9B (or $1.4B), and EV of CNY 9.5B (or $1.3B).
See Yixintang Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.4B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Yixintang Pharmaceutical has market cap of $1.4B and EV of $1.3B.
Yixintang Pharmaceutical's trades at 0.5x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Yixintang Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yixintang Pharmaceutical has a P/E ratio of 32.1x.
See valuation multiples for Yixintang Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 10.7x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 16.5x | XXX | 16.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.1x | XXX | 86.6x | XXX | XXX | XXX |
| EV/FCF | 7.0x | XXX | 6.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYixintang Pharmaceutical's last 12 month revenue growth is 9%
Yixintang Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Yixintang Pharmaceutical's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yixintang Pharmaceutical's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Yixintang Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | -22% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yixintang Pharmaceutical acquired XXX companies to date.
Last acquisition by Yixintang Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Yixintang Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Yixintang Pharmaceutical founded? | Yixintang Pharmaceutical was founded in 2000. |
| Where is Yixintang Pharmaceutical headquartered? | Yixintang Pharmaceutical is headquartered in China. |
| Is Yixintang Pharmaceutical publicy listed? | Yes, Yixintang Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Yixintang Pharmaceutical? | Yixintang Pharmaceutical trades under 002727 ticker. |
| When did Yixintang Pharmaceutical go public? | Yixintang Pharmaceutical went public in 2014. |
| Who are competitors of Yixintang Pharmaceutical? | Similar companies to Yixintang Pharmaceutical include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's current market cap is $1.4B |
| What is the current revenue of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months revenue is $2.6B. |
| What is the current revenue growth of Yixintang Pharmaceutical? | Yixintang Pharmaceutical revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Yixintang Pharmaceutical? | Current revenue multiple of Yixintang Pharmaceutical is 0.5x. |
| Is Yixintang Pharmaceutical profitable? | Yes, Yixintang Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months EBITDA is $123M. |
| What is Yixintang Pharmaceutical's EBITDA margin? | Yixintang Pharmaceutical's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Yixintang Pharmaceutical? | Current EBITDA multiple of Yixintang Pharmaceutical is 10.7x. |
| What is the current FCF of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months FCF is $190M. |
| What is Yixintang Pharmaceutical's FCF margin? | Yixintang Pharmaceutical's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Yixintang Pharmaceutical? | Current FCF multiple of Yixintang Pharmaceutical is 7.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
